Navigation Links
Intervet/Schering-Plough Animal Health Outlines Strength of the Combination
Date:4/30/2008

First batch of bluetongue Bovilis BTV8 vaccine released to supply Northern

European countries

BOXMEER, Netherlands, April 30 /PRNewswire-FirstCall/ -- Intervet/Schering-Plough Animal Health (NYSE: SGP) released the first batch of Bovilis BTV8 vaccine against bluetongue to supply in Northern Europe. The animal health company, combining after the acquisition in 2007 the strength of Intervet and Schering-Plough Animal Health, is not only the world market leader in the production of animal health vaccines, but also one of the world's leaders in the field of animal health.

"Within the animal health sector, there has been a recent emphasis on prevention rather than treatment," says Ruurd Stolp, D.V.M., Ph.D., Senior Vice President and President Global Animal Health. "Our goal is to develop innovative vaccines that address unmet needs and improve disease protection as well as the duration of that protection. When animal diseases are not prevented, the social economic and environmental costs to humans are potentially significant." One prominent example is bluetongue, a devastating disease of ruminants that emerged in Northern Europe since the summer of 2006. The combined animal health unit is uniquely positioned to respond to this need and to deliver effective and timely care.

Intervet/Schering-Plough Animal Health has now released the first batch of bluetongue vaccine for sheep and cattle, Bovilis BTV8, fulfilling firm orders received from a number of countries within Europe. Stolp: "We put great effort into the development of our safe and efficacious Bovilis BTV8 vaccine to meet the urgent need as quickly as possible and we are pleased that production is on track, so that we are able to deliver the first amounts of vaccine before the actual start of the "midge season".

Intervet/Schering-Plough Animal Health has developed the Bovilis BTV8 vaccine in a very short period of time. It has been two years since the emergence of the virus in Northern Europe in 2006. The company supplies Bovilis BTV8 vaccine to a number of European countries. At this moment the supply is in balance with the confirmed orders and undecided tender applications.

Stolp: "While the development of effective disease prevention is important, veterinarians also need innovative treatments for a wide variety of diseases. The combination strengthens our innovation-driven, science-centered approach and allows us to complete our broad pharmaceutical segment and to focus on growth opportunities, geographically or in certain product categories and key species segments. As a global leader in animal vaccines, we are concerned with the global health issues and are in a position to take a leadership role in helping to control some threatening infectious diseases."

Schering-Plough's animal health business, with products originating from both Intervet and Schering-Plough Animal Health (SPAH), offers pharmaceuticals and vaccines for companion animals that enable pets and humans to enjoy their time together, as well as a comprehensive portfolio for livestock to help keep them healthy and ensure a safe, wholesome food supply.

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is http://www.schering-plough.com.


'/>"/>
SOURCE Intervet/Schering-Plough Animal Health
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. BoVir(R) Named Best New Veterinary Diagnostics Product in International Animal Pharm Awards
2. Nobel Award in Medicine Holds Strong Messsage for Animal Activists
3. InVitrias Animal Free Lacromin(TM) Provides a Cost-Effective Improvement Over Transferrin
4. Odyssey Thera Granted U.S. Patent for Animal Imaging
5. Kiwa Signs Letter of Intent with Huaxing Animal Medicine
6. Researchers use magnetism to target cells to animal arteries
7. Smithfield Foods, Inc. Statement Regarding Animal Cloning
8. Collaborative Biosecurity Research Initiative Launched to Target Animal and Public Health Threats Nationally
9. Animal Protection Groups Condemn FDAs Endorsement of Animal Cloning
10. Start Licensing, Inc. Welcomes FDAs Finding of Safety of Food From Cloned Animals
11. Study Shows Coronado Biosciences Bcl-2 Inhibitor, Apogossypol, is More Efficacious, Less Toxic than Gossypol in Animal Models
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... 30, 2016  The Allen Institute for Cell ... first publicly available collection of gene edited, fluorescently ... key cellular structures with unprecedented clarity. Distributed through ... tools are a crucial first step toward visualizing ... what makes human cells healthy and what goes ...
(Date:11/30/2016)... Nov. 30, 2016  Tempus, a technology company ... and Penn,s Abramson Cancer Center have partnered to ... response to immunotherapy treatment based on next generation ... part of a research collaboration, Tempus will provide ... cancer patient data to Penn. Utilizing next-generation sequencing, ...
(Date:11/30/2016)... 2016   Merck , ein führendes ... einer Reihe von Vereinbarungen mit Evotec AG ... Screeningleistungen für Mercks Palette genetischer Reagenzien wie ... diese Bibliotheken in Kombination mit Evotecs Expertise ... zur Ermittlung und Erforschung neuer Arzneimitteltargets.    ...
(Date:11/30/2016)... BILLERICA, Mass. , Nov. 30, 2016   ... announced that it has entered into a set of ... screening services for Merck,s collection of genetic reagents such ... libraries with Evotec,s screening expertise offers an accelerated pathway ... "Drug discovery starts with the identification of new targets, ...
Breaking Biology Technology:
(Date:11/21/2016)...   Neurotechnology , a provider of high-precision ... that the MegaMatcher On Card fingerprint matching algorithm ... NIST Minutiae Interoperability Exchange (MINEX) III ... of the evaluation protocol. The ... fingerprint templates used to establish compliance of template ...
(Date:11/15/2016)... 15, 2016  Synthetic Biologics, Inc. (NYSE MKT: ... on the gut microbiome, today announced the pricing ... of its common stock and warrants to purchase ... price to the public of $1.00 per share ... from the offering, excluding the proceeds, if any ...
(Date:6/22/2016)... 2016  The American College of Medical Genetics and Genomics ... as one of the fastest-growing trade shows during the ... Bellagio in Las Vegas . ... growth in each of the following categories: net square feet ... of attendees. The 2015 ACMG Annual Meeting was ranked 23 ...
Breaking Biology News(10 mins):